Ovarian function suppression with a GnRH analogue: D-ser(But[t])[6]-Arzgly[10]-LHRH (Goserelin) in hormone dependent canine mammary cancer.

Lombardi P, Florio S, Pagnini U, Crispino A, Avallone L

Journal of veterinary pharmacology and therapeutics1 Feb 1999Cited by 15 (Europe PMC)

PMID10211718DOI10.1046/j.1365-2885.1999.00184.xPepBankPUB-10211718

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In dogs with mammary cancer, goserelin decreased circulating oestradiol.
In plain wordsIn dogs with mammary cancer, goserelin decreased circulating oestradiol.
Peptide
Goserelin
Outcome
DecreaseCirculating oestradiol
Study
dogsn = 9
hormone-dependent mammary cancer
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
60 microg/kg every 21 days · 12 monthsAs given in this study (dogs).
Source sentences
Summary
Goserelin treatment decreased circulating levels of oestradiol and progesterone and reduced the size of mammary tumours; all the animals showed objective response (OR) to treatment after 3 months, and the relapse-free survival after 2 years was 88%.
2 context sentences(design, population, supporting numbers)
Summary · context
The aim of the present study was to evaluate the activity of the luteinizing hormone-releasing hormone (LHRH)-agonist, D-ser(But[t])[6]-Azgly[10]-LHRH (Goserelin) in hormone-dependent mammary cancer in dogs.
Summary · context
nine dogs not treated with Goserelin (Group 1) referred to as control; and nine dogs treated with 60 microg/kg depot Goserelin every 21 days for 12 months (Group 2).
Report a problemFND-1021171801
02AnimalAnimal study (in vivo)Efficacy outcome
In dogs with mammary cancer, goserelin decreased circulating progesterone.
In plain wordsIn dogs with mammary cancer, goserelin decreased circulating progesterone.
Peptide
Goserelin
Outcome
DecreaseCirculating progesterone
Study
dogsn = 9
hormone-dependent mammary cancer
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
60 microg/kg every 21 days · 12 monthsAs given in this study (dogs).
Source sentences
Summary
Goserelin treatment decreased circulating levels of oestradiol and progesterone and reduced the size of mammary tumours; all the animals showed objective response (OR) to treatment after 3 months, and the relapse-free survival after 2 years was 88%.
2 context sentences(design, population, supporting numbers)
Summary · context
The aim of the present study was to evaluate the activity of the luteinizing hormone-releasing hormone (LHRH)-agonist, D-ser(But[t])[6]-Azgly[10]-LHRH (Goserelin) in hormone-dependent mammary cancer in dogs.
Summary · context
nine dogs not treated with Goserelin (Group 1) referred to as control; and nine dogs treated with 60 microg/kg depot Goserelin every 21 days for 12 months (Group 2).
Report a problemFND-1021171802
03AnimalAnimal study (in vivo)Efficacy outcome
In dogs with mammary cancer, goserelin reduced mammary tumour size.
In plain wordsIn dogs with mammary cancer, goserelin reduced mammary tumour size.
Peptide
Goserelin
Outcome
DecreaseMammary tumour size
Study
dogsn = 9
hormone-dependent mammary cancer
Outcome group
Tumor growth · Cancer
Studied dose
60 microg/kg every 21 days · 12 monthsAs given in this study (dogs).
Source sentences
Summary
Goserelin treatment decreased circulating levels of oestradiol and progesterone and reduced the size of mammary tumours; all the animals showed objective response (OR) to treatment after 3 months, and the relapse-free survival after 2 years was 88%.
2 context sentences(design, population, supporting numbers)
Summary · context
The aim of the present study was to evaluate the activity of the luteinizing hormone-releasing hormone (LHRH)-agonist, D-ser(But[t])[6]-Azgly[10]-LHRH (Goserelin) in hormone-dependent mammary cancer in dogs.
Summary · context
nine dogs not treated with Goserelin (Group 1) referred to as control; and nine dogs treated with 60 microg/kg depot Goserelin every 21 days for 12 months (Group 2).
Report a problemFND-1021171803
04AnimalAnimal study (in vivo)Efficacy outcome
In dogs with mammary cancer, all goserelin-treated animals showed objective response after 3 months.
In plain wordsIn dogs with mammary cancer, all goserelin-treated animals showed objective response after 3 months.
Peptide
Goserelin
Outcome
Not applicableObjective response
Study
dogsn = 9
hormone-dependent mammary cancer
Outcome group
Tumor growth · Cancer
Studied dose
60 microg/kg every 21 days · 12 monthsAs given in this study (dogs).
Source sentences
Summary
Goserelin treatment decreased circulating levels of oestradiol and progesterone and reduced the size of mammary tumours; all the animals showed objective response (OR) to treatment after 3 months, and the relapse-free survival after 2 years was 88%.
2 context sentences(design, population, supporting numbers)
Summary · context
The aim of the present study was to evaluate the activity of the luteinizing hormone-releasing hormone (LHRH)-agonist, D-ser(But[t])[6]-Azgly[10]-LHRH (Goserelin) in hormone-dependent mammary cancer in dogs.
Summary · context
nine dogs not treated with Goserelin (Group 1) referred to as control; and nine dogs treated with 60 microg/kg depot Goserelin every 21 days for 12 months (Group 2).
Report a problemFND-1021171804
05AnimalAnimal study (in vivo)Efficacy outcome
In dogs with mammary cancer, relapse-free survival after goserelin treatment was 88% after 2 years.
In plain wordsIn dogs with mammary cancer, relapse-free survival after goserelin treatment was 88% after 2 years.
Peptide
Goserelin
Outcome
Not applicableRelapse-free survival
Study
dogsn = 9
hormone-dependent mammary cancer
Outcome group
Tumor growth · Cancer
Studied dose
60 microg/kg every 21 days · 12 monthsAs given in this study (dogs).
Measurements
Relapse-free survival
88%
after 2 years
Source sentences
Summary
Goserelin treatment decreased circulating levels of oestradiol and progesterone and reduced the size of mammary tumours; all the animals showed objective response (OR) to treatment after 3 months, and the relapse-free survival after 2 years was 88%.
2 context sentences(design, population, supporting numbers)
Summary · context
The aim of the present study was to evaluate the activity of the luteinizing hormone-releasing hormone (LHRH)-agonist, D-ser(But[t])[6]-Azgly[10]-LHRH (Goserelin) in hormone-dependent mammary cancer in dogs.
Summary · context
nine dogs not treated with Goserelin (Group 1) referred to as control; and nine dogs treated with 60 microg/kg depot Goserelin every 21 days for 12 months (Group 2).
Report a problemFND-1021171805
06AnimalAnimal study (in vivo)Safety outcome
In dogs with mammary cancer, monthly laboratory tests and physical examination showed no toxic effects of goserelin.
In plain wordsIn dogs with mammary cancer, laboratory tests and physical examination showed no toxic effects of goserelin.
Peptide
Goserelin
Outcome
Not applicableToxic effects
Study
dogsn = 9
hormone-dependent mammary cancer
Outcome group
Adverse events · Whole body
Studied dose
60 microg/kg every 21 days · 12 monthsAs given in this study (dogs).
Source sentences
Summary
Haematology and blood chemistry parameters, measured every month from the beginning of treatment, as well as physical examination, showed that the drug was without toxic effects.
2 context sentences(design, population, supporting numbers)
Summary · context
The aim of the present study was to evaluate the activity of the luteinizing hormone-releasing hormone (LHRH)-agonist, D-ser(But[t])[6]-Azgly[10]-LHRH (Goserelin) in hormone-dependent mammary cancer in dogs.
Summary · context
nine dogs not treated with Goserelin (Group 1) referred to as control; and nine dogs treated with 60 microg/kg depot Goserelin every 21 days for 12 months (Group 2).
Report a problemFND-1021171806

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.